Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight, 2025" report delivers comprehensive insights about 120+ companies and 140+ pipeline drugs currently in the various s ...

The FDA has granted Fast Track designation to nadunolimab to treat patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for gr ...

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further ...

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further devel ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...

SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in Latin America, while ...

Nipocalimab-aahu is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds with high affinity to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.

AU-007 is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other ...